May, 2024- Global biopharmaceutical company, GSK, will become the first founding partner of the Fleming Initiative, an innovative and collaborative approach led by Imperial College Healthcare NHS Trust and Imperial College London to tackle antimicrobial resistance (AMR) around the world.
AMR is widely recognised, including by the World Health Organization, as an urgent global public health threat. In 2019 there were an estimated 1.2 million deaths directly attributable to drug-resistant bacterial infections and as many as 10 million people could die annually from AMR by 2050, resulting in global economic damage of up to $100 trillion by 2050 without effective action.
However, The Fleming Initiative’s unique and transformative approach will bring together world-class scientific, technology, policy and behavioural science expertise with clinical experience in a global network of centres to find, test, and scale solutions to AMR.
Moreover, GSK’s £45 million pledge would be available for approved projects to harness new technology including AI to better interpret and use complex scientific data, identify new opportunities to develop novel treatments and interventions, improve understanding of how drug-resistant infections are transmitted and can be prevented, and understand how better surveillance approaches might improve detection and tracking of infections. The Initiative will also have a strong focus on diagnostics so that the right antimicrobial drugs are given to those who need them, and on education and public engagement to support behavioural change to reduce AMR.
Also Read: DoH inks partnership with GSK to Establish Regional Vaccine Distribution Hub
Emma Walmsley, GSK CEO said: “This will be an important collaboration for GSK building on our long-standing commitment to tackling AMR and our focus on disease prevention. The Fleming Initiative will bring together global resources and expertise from across different sectors to better understand the factors contributing to this growing threat and most importantly, drive action and solutions. We are proud to be a founding partner, and hope others will join us to support this urgent priority”.
Click here to join our WhatsApp channel
Lord Darzi, Chair of the Fleming Initiative, said: “Alexander Fleming’s extraordinary discovery was brought to the world through partnership with industry. As we approach the centenary of his breakthrough, we are delighted that GSK will be a founding partner for the Fleming Initiative – bringing their invaluable expertise and experience to help ensure collective action and protect generations to come.”
Professor Tim Orchard, Chief Executive of Imperial College Healthcare NHS Trust said: “Antimicrobial resistance remains one of the biggest challenges we face in the NHS and other healthcare systems around the world. The support of a global biopharma company with a proven history in treatment for infectious disease is a major boost to our goal to find new solutions and interventions for tackling drug-resistant infections.’’
Professor Hugh Brady, President of Imperial College London, said: “Antimicrobial resistance is one of the most serious challenges facing humanity. The Fleming Initiative will see Imperial build on its impressive track record of societal engagement, policy research and convergence science to tackle this issue head-on. Importantly, it is a global initiative involving partnership at unprecedented scale with leading pharmaceutical companies such as GSK, research funding agencies, philanthropists, health systems and governments.
Furthermore, Health Minister Andrew Stephenson said: “AMR is one of the biggest threats to our society and it’s excellent that private organisations are supporting global efforts to tackle it. I applaud GSK for providing significant funding to support the brilliant work of the Fleming Initiative, bringing together world-renowned science, research and technology to protect the international community.”
